How AI-Powered Personalization Reshapes Medication Initiation and Adherence
Healthcare can sometimes feel like a maze, especially when it comes to keeping patients on therapy. From cardiovascular diseases to neurological conditions, positive outcomes are only possible when medications are used correctly. That’s where AllazoHealth steps in – our AI-powered personalization goes beyond the usual rules-based patient support strategies, delivering better results and improved patient outcomes.
Let’s discover some of the impacts AllazoHealth has had and see how our solution is revolutionizing patient support programs and making a real, personalized difference for patients across several therapeutic areas.
Asthma, affecting 25 million Americans and a staggering 262 million globally, presents a common and costly healthcare challenge. While effective therapies exist, non-adherence to asthma medications has a significant, negative impact on health outcomes and escalates the cost of care.
Patients face various obstacles to adherence, such as:
- Condition-related barriers
- Socioeconomic barriers
- Medication-related barriers
- Behavioral barriers
To address non-adherence to asthma medication, a strategic approach is necessary. Simplifying medication regimens, improving patient education, employing reminder systems, and personalizing patient support programs are key strategies.
Leveraging AI, like AllazoHealth’s AI Platform, can be pivotal in identifying high-risk patients and delivering personalized interventions, ultimately improving their experience, adherence, and bridging therapy gaps. These proactive and personalized measures offer hope for a future where asthma management is more effective and patient-centric.
Unlocking the potential of personalized patient experiences, AllazoHealth’s AI boosted adherence to anticoagulants, resulting in a remarkable 6.9 percent increase in patients’ days on therapy. This tangible improvement not only underscores the impact of AI-driven interventions in patient support programs but also emphasizes adherence’s pivotal role in enhancing heart health. The synergy of innovative technology and patient-centric approaches is steering manufacturers toward a future where tailored interventions lead to improved overall well-being.
Diabetes, the seventh leading cause of death in the U.S., grapples with shockingly low medication adherence rates, hindering effective management despite available treatments. A 2016 study revealed that 45 percent of patients with type 2 diabetes struggle with glycemic control due to medication non-adherence. The consequences are dire: hospitalizations, soaring healthcare costs, and complications like amputations, all contributing to the staggering one-fourth of healthcare dollars dedicated to diabetes care.
AllazoHealth’s AI can intervene, identifying vulnerable patient populations and tailoring outreach to improve therapy initiation and adherence. With an annual healthcare cost of $16,000 per adherent patient, the $24.6 billion incurred due to diabetes non-adherence underscores the urgency for targeted solutions. Human costs, from missed work and diminished quality of life to increased risks of cardiovascular disease and premature death, demand a personalized approach.
AllazoHealth’s AI Platform addresses these complexities, ensuring optimized interventions that meet patients where they are, resulting in improved medication adherence, reduced healthcare costs, and, ultimately, enhanced patient care and support.
Nearly 50 percent of patients with major depressive disorder (MDD) discontinue their medication, posing a significant challenge when it comes to adherence. However, with AllazoHealth’s AI-powered personalization, a prominent pharmaceutical company optimized patient interventions and achieved a 13.3 percent increase in patients’ length of therapy, assessed 180 days post-program enrollment.
Notably, the AI-driven optimization substantially enhanced the impact of emails on therapy duration, making them up to 4.2 times more effective for patients on the MDD drug. This success underscores the potential of AI-driven personalization to improve engagement and address adherence barriers to improve outcomes in the treatment of MDD.
Revolutionizing Medication Initiation and Adherence with AllazoHealth
The transformative power of AllazoHealth’s AI platform is reshaping medication adherence across diverse therapeutic areas is unmistakable. From asthma to neurological conditions, cardiovascular diseases, diabetes, and behavioral health, our innovative approach goes beyond conventional patient support program strategies, yielding tangible improvements in patient outcomes.
By addressing barriers unique to each patient, such as socioeconomic factors, lack of routine or perceived risks, and complex treatment regimens, our AI platform optimizes interventions by content, channel, timing, and cadence to significantly enhance adherence. The success stories span various health domains, from boosting adherence to blood thinners to increasing the length of therapy for an MDD. These stories underscore the potential of AI solutions in pharma.
And in a time when healthcare costs are soaring, and patient well-being is paramount, AllazoHealth’s AI-powered personalization is a necessary solution to medication initiation and adherence. By reducing non-adherence-associated costs and improving patient care and support, our platform paves the way for a future where healthcare is personalized and optimized for better outcomes and enhanced quality of life.